BECN1 and neoplasm: The lack of effectivity was noticed when tumor-bearing animals were treated with MitoX; however, the silencing of Beclin-1 in B16F10 cells overcomes drug tumor resistance, which was characterized by an increase in infiltrating CD8 T cells and a decrease in Foxp3 and Arginase 1 positive cells in the TME, highlighting the role of secretory autophagy in treatment response.